Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression but it is invariably followed by drug resistance. In characterizing early transcriptional changes following drug treatment of mutant EGFR-addicted cells, we identified the stem cell transcriptional regulator SOX...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:eLife
Autors principals: Rothenberg, S Michael, Concannon, Kyle, Cullen, Sarah, Boulay, Gaylor, Turke, Alexa B, Faber, Anthony C, Lockerman, Elizabeth L, Rivera, Miguel N, Engelman, Jeffrey A, Maheswaran, Shyamala, Haber, Daniel A
Format: Artigo
Idioma:Inglês
Publicat: eLife Sciences Publications, Ltd 2015
Matèries:
Human Biology and Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384750/
https://ncbi.nlm.nih.gov/pubmed/25686219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.06132
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars